A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

Exclusion Criteria

• •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
• •Pregnant female subjects; breastfeeding female subjects; female subjects of childbearing potential
• •Fertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product
• •Have a clinically significant infection currently or within 6 months of first dose of study drug
• •Psoriasis Participants:
• •Currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis
• •Have a clinically significant infection currently or within 6 months of first dose of study drug, or a history of chronic or recurrent infectious disease
• •Pregnant female subjects; breastfeeding female subjects; female subjects of childbearing potential
• •Fertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product